	US 12,435,023 B2
	Crystal form of Treprostinil sodium salt and preparation method therefor
Wei Li, Shanghai (CN); and Yi Ren, Shanghai (CN)
Assigned to SHANGHAI FOREFRONT PHARMCEUTICAL CO., LTD., Shanghai (CN)
Appl. No. 17/612,491
Filed by Shanghai Forefront Pharmaceutical Co., Ltd, Shanghai (CN)
PCT Filed May 20, 2020, PCT No. PCT/CN2020/091218 § 371(c)(1), (2) Date Nov. 18, 2021, PCT Pub. No. WO2020/233588, PCT Pub. Date Nov. 26, 2020.
Claims priority of application No. 201910425686.1 (CN), filed on May 21, 2019; and application No. 201910899910.0 (CN), filed on Sep. 23, 2019.
Prior Publication US 2022/0242811 A1, Aug. 4, 2022
Int. Cl. C07C 59/72 (2006.01); A61K 31/192 (2006.01); A61K 45/06 (2006.01); C07C 51/43 (2006.01)

CPC C07C 59/72 (2013.01) [A61K 31/192 (2013.01); A61K 45/06 (2013.01); C07C 51/43 (2013.01); C07B 2200/13 (2013.01)]

8 Claims

1. A five-and-a-half hydrate of Treprostinil sodium salt, or a hydrate partially dehydrated crystal form II thereof,

wherein the powder X-ray diffraction (Cu-Ka, 1.54178 Å) pattern of the five-and-a-half hydrate of Treprostinil sodium salt has characteristic peaks at the following 2Theta angle positions:

4.3°±0.2°, 8.7°±0.2° and 17.6°±0.2°;

and

the powder X-ray diffraction (Cu-Ka, 1.54178 Å) pattern of the hydrate partially dehydrated crystal form II of the five-and-a-half hydrate of Treprostinil sodium salt has characteristic peaks at the following 2Theta angle positions:

5.3°±0.2°, 10.6°±0.2° and 16.0°±0.2°.